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ABSTRACT  
Objective: To study retention in care (RIC) trajectories and associated factors in patients eligible 
for antiretroviral treatment (ART) in a universal test-and-treat setting (TasP trial, South Africa, 
2012-2016).  
Design: A cluster-randomized trial whereby individuals identified HIV-positive after home-based 
testing were invited to initiate ART immediately (intervention) or following national guidelines 
(control). 
Methods: Exiting care was defined as ≥3 months late for a clinic appointment, transferring 
elsewhere, or death. Group-Based Trajectory Modelling was performed to estimate RIC 
trajectories over 18 months and associated factors in 777 ART-eligible patients.  
Results: Four RIC trajectory groups were identified: i) group 1 “remained” in care (reference, 
n=554, 71.3%), ii) group 2 exited care then “returned” after (median [interquartile range]) 4 [3-
9] months (n=40, 5.2%), iii) group 3 “exited care rapidly” (after 4 [4-6] months, n=98, 12.6%), 
iv) group 4 “exited care later” (after 11 [9-13] months, n=85, 10.9%). Group 2 patients were less 
likely to have initiated ART within 1 month and more likely to be male, young (<29 years), 
without a regular partner and to have a CD4 count >350 cells/mm3. Group 3 patients were more 
likely to be women without social support, newly diagnosed, young, and less likely to have 
initiated ART within 1 month. Group 4 patients were more likely to be newly diagnosed and aged 
≤39 years.  
Conclusions: High CD4 counts at care initiation were not associated with a higher risk of exiting 
care. Prompt ART initiation and special support for young and newly diagnosed HIV-patients are 
needed to maximize RIC. 
 
Keywords: universal test and treat, HIV, South Africa, retention in care, trajectories  
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INTRODUCTION  
South Africa has the highest number of people living with HIV (PLWHIV) in the world, estimated 
at 7 million in 2015 (1). Forty-nine percent receive antiretroviral therapy (ART), making it the 
largest treatment programme worldwide (2). Despite a reduction in HIV-related morbidity and 
mortality and a consequent increase in life expectancy (3), HIV incidence remains unacceptably 
high (4). 
In 2016, South Africa adopted the WHO’s recommendation to implement a universal test-and-
treat (UTT) strategy for HIV (4). The success of this strategy depends on sustained retention in 
care (RIC) (5,6). Modelling estimated that in order to achieve an HIV incidence rate below 0.1% 
per year by 2050, rates of ART coverage and RIC need to reach 95% (5). 
A meta-analysis in 2015 estimated that RIC among adults who initiated ART in South Africa was 
77% at 12 months and 75% at 24 months (7). In 2017, the South African government set the 
objective of reaching a retention rate of 90% at 12 months after ART initiation among PLWHIV 
by 2018/19, increasing to 95% by 2021/22 (4). 
In order to achieve this ambitious target, a greater understanding of the barriers to RIC in UTT 
settings, where PLWHIV start treatment early, is needed. To date, literature in low- and middle-
income countries has mainly focused on non-RIC among pre-ART patients (8–10) or patients 
who start ART with low CD4 counts (≤350 cells/mm3) and/or at AIDS stage (11–13). Evidence 
suggests a lower RIC rate among pre-ART patients with high CD4 counts (9,10,14), but it is still 
unknown whether high CD4 counts (>350 cells/mm3) at ART initiation will improve or 
deteriorate RIC. In the only study conducted to date in a UTT setting - the SEARCH trial in 
Uganda and Kenya - the authors found high RIC among patients with high CD4 counts (350-500 
cells/mm3, and >500 cells/mm3) (15). However, concerns remain that patients with high CD4 
counts may be more reluctant to engage in treatment (16). Moreover, one limitation of previous 
RIC studies is the assumption that patients follow a single care trajectory while, in reality, patients 
can cycle in and out of care, and so multiple trajectories are possible (17,18). 
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In this study, we aimed to study RIC trajectories and associated factors in ART-eligible patients 
enrolled in the UTT TASP trial ANRS 12249 implemented in rural South Africa.   
 
METHODS  
Study setting and design 
ANRS-12249 TasP (Treatment as Prevention) trial was a cluster-randomized trial conducted 
between 2012-2016 in the Hlabisa sub-district, KwaZulu-Natal, in South-Africa. The area is 
mainly rural with scattered homesteads. It is also among the most exposed to HIV in the country 
(19) with an estimated 30% HIV prevalence in adults (15-49 years) (20). The main objective of 
the trial was to investigate whether HIV testing of all adult populations followed by immediate 
ART initiation for all those testing positive (irrespective of immunological status or clinical stage) 
would reduce HIV incidence in this area. 
The trial protocol is described elsewhere (21,22). Briefly, it was implemented in 22 (11 
intervention and 11 control) geographic clusters, each with an average population of 1000 
residents ≥16 years. In all clusters, home-based counselling and HIV testing (HBCT) were offered 
every six months to all eligible household members, i.e. residents ≥16 years. Individuals testing 
HIV-positive were then referred to their cluster trial clinic. These clinics which were set up 
specifically for the trial, were located <5 km from their homes. The clinics in the intervention 
clusters immediately offered ART to all PLWHIV regardless of CD4 count or clinical stage. 
Instead, PLWHIV in the control clinics initiated ART according the eligibility criteria defined by 
national guidelines: CD4 count ≤350 cells/mm3, WHO stage 3/4, and/or pregnancy (23). In 
January 2015, these criteria were extended to include CD4 count ≤500 cells/mm3, hepatitis B 
positivity and HIV-negative partners in serodiscordant relationships (24). In all the trial clinics, 
patients who initiated ART had monthly clinical follow-up visits, while pre-ART patients had a 
quarterly clinical follow-up. All patients, whether pre-ART or ART-treated, who were more than 
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three months late for an appointment in their clinic, were contacted by phone or during home-
based visits. HIV care was also available in government clinics located in the trial area which also 
provided care to non-HIV patients (25). Upon request, participants could transfer out from trial 
care to one of these clinics, in or outside the trial area.  
The Biomedical Research Ethics Committee (BREC) of KwaZulu-Natal University (BFC 104/11) 
and the South African Medicines Control Council approved the trial. All participants provided 
written informed consent.  
Outcome 
The study outcome was a time-varying binary variable “retention in trial care” (RIC) status, 
describing whether a patient remained or not in trial care during the 18-month study period. A 
patient was considered to have exited trial care if s/he was >3 months late for his/her last 
appointment at the clinic, if s/he transferred out or if s/he died. RIC status in the trial clinics was 
assessed for each patient every month from 4 to 18 months after his/her baseline visit (RIC status 
was therefore not defined during the first four months of follow-up). A patient lost to follow-up 
(LTFU) at a given month could re-enter trial care if s/he revisited a trial clinic later. 
Study population and study period 
The study population included HIV-positive individuals eligible to initiate ART (as per the trial 
protocol) at their first visit in one of the trial’s clinics (baseline visit), who had their baseline visit 
≥18 months before the end of the trial (30th June 2016), and who did not die in the first 4 months 
of follow-up. The study period covered from 4 to 18 months after the baseline visit of each patient. 
Covariates 
Information on covariates used in the analysis was obtained from (i) face-to-face questionnaires 
administered during home-based visits and at baseline visit in clinics, and (ii) clinical report forms 
completed by caregivers at baseline and during follow-up.  
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Covariate information collected during home-based visits included gender, age, education, having 
children, occupation, household wealth, and geographical accessibility to the trial’s clinics. 
Covariates collected at the baseline clinic visit included CD4 count, having a regular partner, 
social support, psychological distress (Patient Health Questionnaire-4 scale (26)), time between 
referral and baseline visit, and being newly diagnosed at referral (i.e., reporting - during HBHT - 
no previous HIV-positive diagnosis and not being registered as a HIV patient in local government 
clinics). We also distinguished patients who initiated ART within one month after baseline from 
those who did not. Finally, we classified the 22 clusters into a binary variable: (i) clusters with 
low number of patients (13-155) followed in the trial’s clinics (HIV prevalence in those clusters 
was 17.5%-35.4%), (ii) clusters with high number of patients (212-422) followed in the trial’s 
clinics (HIV prevalence: 32.3-39.4%).  
Statistical analysis 
Group-Based Trajectory Modelling (GBTM) was performed to estimate RIC trajectories during 
the study period using the outcome variable “retention in trial care”. GBTM is a semi-parametric 
mixture modelling procedure for longitudinal data (27), which identifies trajectory groups over 
time. It classifies individuals into groups with similar evolution for the outcome variable, and 
identifies factors associated with these groups.  
The optimal number of trajectory groups was evaluated using the Bayesian Information Criterion 
(BIC), by selecting the number of groups that best represented the heterogeneity between the 
trajectories.  
The probabilities of group membership were estimated using a multinomial logistic model. 
Patients were assigned to the group for which they had the highest estimated probability of 
membership. Each identified group had a specific trajectory that illustrated the probabilities of 
having exited care at a given month from 4 to 18 months after baseline. We assumed that the 
probability of exiting care followed a binary logit distribution. 
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Factors associated with trajectory group membership were tested for in the analysis as fixed 
covariates measured at the baseline visit and at one month after baseline for the ART initiation 
covariate. The model parameters were estimated using the maximum likelihood method.  
Covariates were considered eligible for the GBTM multivariable model if their association with 
group membership indicated a p-value <0.20 in GBTM univariable analyses. A forward stepwise 
procedure was used to select the covariates in the final multivariable model with a p-value ≤0.05.  
All analyses were performed using Stata/SE 12.1 for Windows software (28). 
Sensitivity analysis 
Sensitivity analysis were conducted to assess the robustness of the results when considering the 
following: i) a longer follow-up period (i.e. from 4 to 24 months after baseline), ii) alternative 
hypotheses for transfers-out. Specifically, we considered transfers-out as missing data from the 
time the patients transferred out (accordingly, exiting trial care only included deaths and LTFU). 
Second, we assessed an optimistic but realistic scenario where transfers-out were considered to 
be “retained in care”. 
 
RESULTS  
Cohort profile 
Of the 7647 PLWHIV who were referred to the trial clinics over the trial period, 3019 (39.5%) 
actually visited a trial clinic at least once. Among these, 1412 (46.8%) were already on ART at 
the baseline visit, 428 (14.2%) were not eligible for ART, and 16 (0.5%) had missing data for 
either ART status or CD4 cell count. Of the remaining 1163 (38.5%) individuals - all eligible to 
initiate ART at baseline - we retained those who had their first visit ≥18 months before the end of 
the trial (788 patients), and excluded those who died during the first four months of follow-up (10 
patients) since retention was not defined during this period, as well as one patient whose recorded 
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date of death was inconsistent. Our study population therefore comprised 777 ART-eligible 
patients (Supplementary Figure 1).  
Approximately two-thirds (70.7%) of our study population were women (Table 1). The median 
age [interquartile range (IQR)] at baseline was 35 [27.5; 46.6] years, and 76.2% had a regular 
partner. Most patients (88.5%) were already diagnosed HIV-positive at referral. Two-thirds 
(66.3%) entered HIV care at one of the trial’s clinics within one month after referral and 40% 
resided <1 km from their clinic. Over a quarter (26.3%) of patients had a CD4 count >500 
cells/mm3 at baseline and 54% initiated ART within one month.  
Retention in care and retention trajectories 
The overall RIC rate was 77.5% at 12 months (M12) and 72.8% at M18 (Figure 1a). Among 
patients exiting trial care, LTFU was the main cause of attrition (76.6% and 73.4% at M12 and 
M18, respectively), while death accounted for 6.9% and 8.1%, respectively, and transfers-out for 
16.6% and 18.5%. The median [IQR] follow-up duration before exiting care for the first time was 
7 [4; 11] months.  
RIC rates at M18 were similar in both arms (70.8% - control versus 73.8% - intervention, p=0.37), 
and between the three different CD4 count categories (71.9%, 77.8% and 69.6% for CD4 counts 
≤350 cells/mm3, 350-500 cells/mm3, and >500 cells/mm3, respectively; p=0.22). In addition, 
focusing only on the 704 (90.6%) patients who initiated ART over the study period, the RIC rate 
at M18 reached 80.0% (79.4% - control versus 80.3% - intervention, p=0.79). 
Four different trajectories were identified (Figure 2). Group 1 patients (71.3% of the study 
population) “remained in care” throughout the study period. At M18, fewer than 1% of them had 
died or transferred out (Figure 1b). Group 2 patients (5.2%) exited care and then returned later, 
after a median time [IQR] of 4 [3-9] months (hereafter the “returned” group). At M18, no deaths 
had occurred in this group and only one patient (2.5%) had transferred out. Group 3 patients 
(12.6%) “rapidly exited” care after a median time [IQR] of 4 [4-6] months of follow-up. In this 
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group, all patients had exited trial care at M18 (8.2% had died and 21.4% had transferred out). 
Finally, Group 4 patients (10.9%) “exited care later” after a median time [IQR] of 11 [9-13] 
months of follow-up. At M18, 9.4% of them had died while 12.9% had transferred out.  
ART initiation by trajectory group 
While all study patients were ART-eligible at baseline, overall 90.6% initiated ART during the 
study period. Furthermore, ART initiation differed widely across the four trajectory groups (Table 
2). In Groups 1 and 4, a large majority of patients initiated ART during the study period (99.6% 
and 87.1%, respectively), mainly during the first month after baseline. In Group 2, a large majority 
(85.0%) also initiated ART during the study period but after a longer delay (median [IQR] time 
after baseline: 343 [208-449] days). Conversely, in Group 3, only 44.9% initiated ART during the 
study period but within a short delay after baseline (median [IQR] time: 27.5 [15.5-49.5] days).  
Factors associated with trajectory groups  
Table 3 presents the results of the univariable and multivariable analyses.  
In the multivariable model, the patients of Group 2 compared with those in Group 1 (reference 
group) were more likely to be young (adjusted odds ratio (aOR) [95% confidence interval 
(CI)]=3.3 [1.4;8.2] for 16-29 years old versus ≥40 years old), without regular partner (2.8 
[1.1;6.8]), men receiving social support (3.4 [1.4;8.3] versus women receiving social support), 
and to have high CD4 counts (7.7 [2.6;23.1] and 5.1 [1.7;15.4] for CD4 counts between 350-500 
cells/mm3 and >500 cells/mm3, respectively, versus CD4 counts ≤350 cells/mm3).  
The patients in Group 3, compared with those in Group 1, were significantly younger (3.9 
[2.1;7.2] for patients aged 16-29 years old versus  ≥40 years old), were more likely to be women 
without social support (2.2 [1.1,4.2] versus women with social support), and newly diagnosed 
(4.2 [2.2;8.2]).  
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By contrast, the patients in Group 2 and those in Group 3, compared with those in Group 1, were 
less likely to have initiated ART within 1 month after baseline (0.03 [0.0;0.2] and 0.2 [0.1;0.3], 
respectively). 
Finally, the patients in Group 4, compared with those in Group 1, were more likely to be young 
(4.6 [2.3;9.3] for 16-29 years old and 2.7 [1.3;5.7] for 30-39 years old versus ≥40 years old), and 
newly diagnosed (5.3 [2.7;10.1]).  
Sensitivity analyses 
When estimating the trajectory groups over a 24-month period (n=536), the retention rate 
decreased to 69.2% at M24 and was similar in both arms (63.9% - control versus 71.4% - 
intervention, p=0.09), and between the three CD4 counts categories at baseline (69.8%, 74.7% 
and 65.6% for CD4 counts ≤350 cells/mm3, between 350-500 cells/mm3, and >500 cells/mm3, 
respectively; p=0.311). A similar pattern including four trajectory groups was identified, but an 
additional group of patients (Group 5) who exited care after a median [IQR] time of 17 [15-20] 
months emerged (Supplementary Figure 2). Group 5 included 41 (7.6%) patients who were all in 
Group 4 of the main analysis (over the 18-month period). The only factor associated with Group 
5 was being a woman without social support (aOR [95% CI]=2.6 [1.1;6.3] versus a woman 
reporting social support), while associated factors for the four other groups were the same as those 
identified in the main analysis.  
When considering transfers-out as missing data, the retention rate at M12 and M18, respectively, 
increased to 80.5% and 76.7%. We found the same associated factors for each group as in the 
main analysis, except for social support, which was no longer significant (Supplementary Table 
1). Similar results were found when considering transfers-out as “remaining in care”: the RIC rate 
at M12 and M18, respectively, increased to 81.2% and 77.9%, and the same associated factors 
were identified (Supplementary Table 2).  
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DISCUSSION  
This study investigated retention in care among HIV-positive patients in Kwazulu-Natal in South 
Africa, who were eligible for ART in a UTT setting where HIV prevalence ranged from 17% in 
very rural areas to 39% in communities close to the zone’s national highway (29). Retention at 
18 months was 72.8% overall and 80.6% if we only consider patients who initiated ART during 
the study period. Furthermore, using an original approach - group-based trajectory modelling - 
we identified care trajectories and their respective associated factors in this population, which is 
central for tailoring and prioritizing interventions. We showed that patterns of engagement with 
care are not uniform. Although three quarters of the study patients remained in care during the 
whole study period, three trajectories for exiting care emerged. Two corresponded to patients who 
left care and did not return during the study period (12.6% exited care after a very short follow-
up duration, while 10.9% left after a longer duration). The third trajectory (5.2%) represented 
patients who exited care relatively rapidly but then returned. Our findings also suggest that 
initiating care in a UTT setting is not associated with lower retention, but that patients with high 
CD4 counts are more likely to exit care and then return. In addition, prompt ART initiation (within 
one month after first visit in a trial clinic) was associated with a lower risk of exiting care rapidly 
and of exiting then returning. The main factors associated with care exit trajectories (either rapidly 
or later) included male gender, young age and being newly diagnosed.  
Retention rates found in our study are slightly higher than those estimated for the same period 
among patients initiating ART in South Africa’s national ART programme (80.6% versus 71%). 
Although relatively high, these retention rates are still well below 95%, the estimated rate needed 
to ensure the eradication of the HIV epidemic (5) and the target set by the 2017-2022 South 
African National Strategic Plan (4). In addition, we found no significant difference in retention 
rates between the trial’s arms, or the CD4 count categories (≤350; 350-500; >500 cells/mm3) at 
baseline. This was confirmed in multivariable analysis where patients with high CD4 counts (350-
500 cells/mm3 and >500 cells/mm3) were not at higher risk of exiting care (either rapidly or later) 
12 
 
than those with CD4 counts ≤350 cells/mm3. These findings suggest that initiating ART early in 
UTT settings is not associated with lower retention, probably because immediate ART initiation 
limits the duration of the pre-ART period, when the risk of exiting care is the highest (30). 
However, we showed that patients with high CD4 counts had a higher risk of exiting care and 
returning afterwards. In addition, ART initiation within 1 month after the first visit to a trial clinic 
was significantly associated with a lower risk of exiting care rapidly (whether subsequently 
returning or not), suggesting that in a UTT setting, rapid ART initiation fosters retention. 
Interestingly, in the “returned” group, despite relatively high ART uptake over 18 months (85%), 
almost 95% of the patients had not initiated ART within 1 month, but did so within approximately 
one year. Delayed ART initiation in those with high CD4 count may be due to patients being 
hesitant to initiate ART rapidly (31), but also due to care providers prioritising patients with lower 
CD4 counts in clinics with high patient loads (32). 
As found in other settings (33,34), retaining young patients in care is a challenge. Indeed, young 
age (<30) was a common risk factor for the three trajectories of care exit. It has been shown that 
this population had more competing life activities preventing them from attending clinical 
appointments on a regular basis (17,31,35). The trial setting was also characterised by a high 
migration level, which may have contributed to lower engagement in care by younger individuals 
who are more mobile (36,37). 
Furthermore, our findings highlight the importance of providing support to newly diagnosed HIV-
positive individuals and of closely accompanying them on the HIV care continuum. Indeed, in 
the TasP trial, these people were less likely to be linked to care (38) and had a higher risk of 
exiting care. This not only suggests that a long delay is required to first accept the disease, and to 
decide whether or not to attend a clinic, but also that newly diagnosed persons who attend a clinic 
may not be ready to engage steadfastly in care. Although such difficulties are not specific to the 
UTT strategy (39,40), they may be more frequent in this setting as this strategy does not rely on 
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a voluntary testing initiative, and therefore people may be less psychologically prepared to receive 
a positive diagnosis. 
In this rural area of Kwazulu-Natal in South Africa, where HIV prevalence has reached extremely 
high levels, interventions are urgently needed to accelerate access to ART and to optimize 
retention in care, with the goal of achieving viral suppression in PLWHIV and reducing new 
infection incidence in the community. Prompt and early ART initiation proposed in a UTT setting 
may be an effective means to reach this objective. In the TasP trial, most of PLWHIV who 
initiated ART within one month had only one visit in a trial clinic before ART initiation. However, 
a non-negligible proportion of our study population (7.2%) never returned after their first visit, 
and a significant proportion of those who exited care during the study period (30.6%) attended 
clinics only once. Considering the importance of the first visit for future retention, a great deal of 
attention should be paid to patients during this visit, in order to adequately prepare them for ART 
initiation. Special attention is needed for the youngest, those newly diagnosed, and those with 
high CD4 counts who may be more hesitant to engage steadfastly in care and may require 
additional visits before initiating ART. Home-based ART initiation is another potential 
intervention which may encourage rapid ART initiation if patients are adequately prepared (41). 
Our study has limitations. First, we focused on RIC only in the trial’s clinics because we lacked 
information about the retention status of patients who transferred out to public or private facilities. 
The latter were assumed to have exited care, which may have led to an underestimation of the 
retention rate. However, sensitivity analyses showed that our results are robust when considering 
alternative hypotheses for transfers-out. Second, although a tracking team contacted patients 
LTFU either by phone or during home-based visits, a certain number of silent transfers may have 
occurred, contributing to an underestimation of the retention rate. This limitation has often been 
mentioned in other studies (42,43). Third, although the TasP trial has been implemented at the 
population level with HIV status ascertained for 83% of adults living in the trial area (29), only 
39.5% (3019/7647) of HIV-positive individuals referred for HIV care during HBHT actually 
attended a trial clinic. However, a significant proportion (42.7%) of the 7647 participants were 
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already in the care of government clinics. Most of the latter (approximately 95%) were already 
ART-treated and thus not eligible for our study. In addition, according to a previous study on 
linkage to care in the trial, the majority (i.e. approximately 72%) of HIV-positive individuals not 
in care at referral were not linked to care at 3 months (either in TasP or in government clinics), 
while those linked to care attended the trial’s clinics and not the government clinics (44). This 
suggests that selection bias is possible but should be limited as the large majority (i.e. 86%) of 
our target population (HIV-positive individuals who initiated care i.e., who were not already being 
treated) were included in the trial’s clinics.  
 
Despite these limitations, this study brings great added value to current knowledge about RIC in 
the context of UTT strategies in Sub-Saharan Africa. Our approach to analysing retention in care 
is innovative and promising, as it does not consider retention as a simple binary variable at a given 
point of time, rather a dynamic phenomenon where patients can cycle in and out of care, with 
multiple possible trajectories. It highlights the different trajectories of disengagement from care, 
and suggests that initiating care in a UTT setting is not associated with lower retention.  
Our findings may also inform policy makers’ decision on the strategies to improve RIC which is 
crucial for maximizing the impact of ART on the reduction of incidence. This includes ensuring 
prompt ART initiation, and targeting young, newly diagnosed patients and those with high CD4 
counts, in particular during initial follow-up visits. 
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Figure 1: Retention in care status of ART-eligible patients at first clinic visit from 4 to 18 
months of clinical follow-up, overall (Figure 1a) and according to trajectory group (Figure 
1b) (ANRS 12249 TasP trial, n=777) 
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Figure 2: Care trajectories in trial clinics over 18 months of clinical follow-up among 
patients eligible for ART initiation at the first visit (ANRS 12249 TasP trial, n=777) 
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Table 1: Descriptive statistics of the study population at first visit according to trajectory 
groups (ANRS 12249 TasP trial, n=777) 
  Trajectory  groups 
 
Total at first 
visit 
n=777 
Group 1: 
remained in 
care n=554 
(71.3%) 
Group 2: 
exited care 
then returned 
n=40 (5.2%) 
Group 3: 
exited care 
rapidly 
n=98 (12.6%) 
Group 4: 
exited care 
later 
n=85 (10.9%) 
Socio-demographic characteristics, n (%)       
Gender      
Male 228 (29.3) 144 (26.0) 18 (45.0) 31 (31.6) 35 (41.2) 
Female 549 (70.7) 410 (74.0) 22 (55.0) 67 (68.4) 50 (58.8) 
Age, median [IQR] years 
35.0 
[27.5-46.6] 
36.8  
[28.5-49.1] 
30.1  
[26.9-45.7] 
29.8  
[24.9-41.7] 
30.2  
[25.7-37.9] 
Age (years)      
16-29 278 (35.8) 165 (29.8) 19 (47.5) 52 (53.1) 42 (49.4) 
30-39 210 (27.0) 158 (28.6) 7 (17.5) 19 (19.4) 26 (30.6) 
≥40 288 (37.1) 230 (41.6) 14 (35.0) 27 (27.6) 17 (20.0) 
Missing 1 (0.1)     
Educational level      
                     Primary or less 340 (43.8) 256 (46.3) 19 (47.5) 37 (37.8) 28 (33.7) 
Some secondary 281 (36.2) 194 (35.1) 14 (35.0) 42 (42.9) 31 (37.4) 
                      Completed secondary 153 (19.7) 103 (18.6) 7 (17.5) 19 (19.4) 24 (28.9) 
Missing 3 (0.4)     
Had a regular partner      
Yes 592 (76.2) 424 (77.5) 28 (70.0) 70 (76.1) 70 (83.3) 
No 171 (22.0) 123 (22.5) 12 (30.0) 22 (23.9) 14 (16.7) 
Missing 14 (1.8)     
Partner HIV status      
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Partner HIV+ 236 (30.4) 179 (36.3) 13 (33.3) 19 (23.2) 25 (32.5) 
Partner HIV- 71 (9.1) 53 (10.8) 2 (5.1) 7 (8.5) 9 (11.7) 
Do not know 213 (27.4) 138 (28.0) 12 (30.8) 34 (41.5) 29 (37.7) 
No partner 171 (22.0) 123 (25.0) 12 (30.8) 22 (26.8) 14 (18.2) 
Missing 86 (11.1)     
Had children      
Yes 675 (86.9) 493 (91.1) 33 (82.5) 78 (81.3) 71 (86.6) 
No 84 (10.8) 48 (8.9) 7 (17.5) 18 (18.7) 11 (13.4) 
Missing 18 (2.3)     
Economic characteristics, n (%)      
Household wealth index§      
Low  317 (40.8) 225 (40.8) 16 (41.0) 44 (44.9) 32 (38.1) 
Middle  308 (39.6) 218 (39.6) 19 (48.7) 37 (37.8) 34 (40.5) 
High  147 (18.9) 108 (19.6) 4 (10.3) 17 (17.4) 18 (21.4) 
Missing 5 (0.6)     
Occupational status       
Employed 111 (14.3) 90 (16.5) 3 (7.7) 8 (8.3) 10 (12.1) 
Seeking employment 221 (28.4) 149 (27.3) 12 (30.8) 30 (30.9) 30 (36.1) 
Other, inactive 433 (55.7) 307 (56.2) 24 (61.5) 59 (60.8) 43 (51.8) 
Missing 12 (1.5)     
Psychosocial variables, n (%)      
Social support      
Yes 582 (74.9) 423 (78.3) 29 (72.5) 61 (67.0) 69 (82.1) 
No 173 (22.3) 117 (21.7) 11 (27.5) 30 (33.0) 15 (17.9) 
Missing 22 (2.8)     
Gender & Social support      
Female & social support 423 (54.4) 320 (59.3) 15 (37.5) 44 (48.4) 44 (52.4) 
Female & no social support 116 (14.9) 82 (15.2) 7 (17.5) 21 (23.1) 6 (7.1) 
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Male & social support 159 (20.5) 103 (19.1) 14 (35.0) 17 (18.7) 25 (29.8) 
Male & no social support 57 (7.3) 35 (6.5) 4 (10.0) 9 (9.9) 9 (10.7) 
Missing 22 (2.8)     
PHQ-4 depression score      
Not depressed 557 (71.7) 398 (73.2) 33 (84.6) 67 (72.8) 59 (70.2) 
Depressed 202 (26.0) 146 (26.8) 6 (15.4) 25 (27.2) 25 (29.8) 
Missing 18 (2.3)     
Clinical variables, n (%)      
On ART at M1      
No 357 (46.0) 210 (37.9) 38 (95.0) 73 (74.5) 36 (42.4) 
Yes 420 (54.0) 344 (62.1) 2 (5.0) 25 (25.5) 49 (57.6) 
Time between referral and first visit      
Less than 1M 515 (66.3) 368 (66.6) 18 (45.0) 72 (74.2) 57 (67.9) 
1-3M 86 (11.1) 64 (11.6) 7 (17.5) 9 (9.3) 6 (7.1) 
More than 3M 173 (22.3) 121 (21.9) 15 (37.5) 16 (16.5) 21 (25.0) 
Missing 3 (0.4)     
Newly diagnosed at referral      
No 686 (88.3) 518 (93.5) 37 (92.5) 72 (74.2) 59 (70.2) 
Yes 89 (11.5) 36 (6.5) 3 (7.5) 25 (25.8) 25 (29.8) 
Missing 2 (0.3)     
CD4 at first visit      
CD4≤350 405 (52.1) 298 (55.1) 5 (12.8) 51 (52.0) 51 (60.7) 
CD4 between ]350-500] 153 (19.7) 106 (19.6) 17 (43.6) 17 (17.4) 13 (15.5) 
CD4>500  204 (26.3) 137 (25.3) 17 (43.6) 30 (30.6) 20 (23.8) 
Missing 15 (1.9)     
Trial arm      
Control  257 (33.1) 182 (32.9) 13 (32.5) 36 (36.7) 26 (30.6) 
Intervention  520 (66.9) 372 (67.2) 27 (67.5) 62 (63.3) 59 (69.4) 
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Geographic accessibility and clusters, n (%)      
Distance to nearest trial clinic      
≤1 km 311 (40.0) 224 (40.6) 17 (43.6) 38 (38.8) 32 (38.1) 
>1 km 462 (59.5) 328 (59.4) 22 (56.4) 60 (61.2) 52 (61.9) 
Missing 4 (0.5)     
Clusters      
         Clusters with low number of patients and 
HIV prevalence  
349 (44.9) 263 (47.5) 8 (20.0) 40 (40.8) 38 (44.7) 
             Clusters with high number of patients 
and HIV prevalence 
428 (55.1) 291 (52.5) 32 (80.0) 58 (59.2) 47 (55.3) 
IQR: interquartile range 
§ Household wealth assets were defined in three categories using a principal component analysis on 
sources of energy, amenities and access to drinking water and toilet facilities (45). 
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Table 2: Patients who initiated ART among the study population according to trajectory 
groups (ANRS 12249 TasP trial, n=777) 
 
n (%) of ART initiation 
within 1 month of 
baseline in TasP clinics 
n (%) of ART initiation 
during the study period 
Median [IQR] days 
between baseline and ART 
initiation 
All 420 (54.1) 704 (90.6) 25 [16-49]  
Group 1: remained in care  344 (62.1) 552 (99.6) 23 [15-42]  
Group 2: exited care then 
returned 
2 (5.0) 34 (85.0) 343.5 [208-449]  
Group 3: exited care 
rapidly 
25 (25.5) 44 (44.9) 27.5 [15.5-49.5]  
Group 4: exited care later 49 (57.7) 74 (87.1) 24 [16-41]  
IQR: interquartile range 
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Table 3: Factors associated with trajectory groups (reference= Group 1: remained in care), univariable and multivariable analyses (ANRS 
12249 TasP trial) 
 
 Univariable analyses 
OR [95% CI] 
 Multivariable analysis 
aOR [95% CI] 
 
 
Covariates 
 Group 2: 
exited care 
then returned 
Group 3: 
exited care 
rapidly 
Group 4: 
exited care 
later 
 Group 2: 
exited care 
then returned 
Group 3: 
exited care 
rapidly 
Group 4: 
exited care 
later 
Gender         
Male  1 1 1  - - - 
Female  2.3* [1.1,4.4] 1.3 [0.8,2.1] 2.0** [1.2,3.2]  - - - 
Age (years)         
≥40   1 1 1  1 1 1 
30-39  0.8 [0.3,1.9] 1.0 [0.5,1.9] 2.2* [1.2,4.4]  1.0 [0.3,2.8] 1.2 [0.6,2.4] 2.7** [1.3,5.7] 
16-29  1.9 [0.9,4.0] 2.7*** [1.6,4.5] 3.5*** [1.9,6.5]  3.3** [1.4,8.2] 3.9*** [2.1,7.2] 4.6*** [2.3,9.3] 
Educational level         
                     Primary or less  1 1 1  - - - 
Some secondary  1.0 [0.5,2.2] 1.5 [0.9,2.4] 1.4 [0.8,2.5]  - - - 
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                      Completed secondary  1.0 [0.4,2.4] 1.3 [0.7,2.3] 2.1* [1.1,3.8]  - - - 
Partner HIV status         
Partner HIV+  1 1 1  - - - 
Partner HIV-  0.5 [0.1,2.4] 1.2 [0.5,3.1] 1.2 [0.5,2.8]  - - - 
Do not know  1.2 [0.5,2.7] 2.3** [1.3,4.3] 1.5 [0.8,2.7]  - - - 
No partner  1.4 [0.6,3.3] 1.7 [0.9,3.3] 0.8 [0.4,1.7]  - - - 
Having a regular partner         
Yes  1 1 1  1 1 1 
No  1.6 [0.8,3.3] 1.1 [0.7,1.8] 0.7 [0.4,1.3]  2.8* [1.1,6.8] 1.5 [0.8,2.8] 1.2 [0.6,2.4] 
Had children         
Yes  1 1 1  - - - 
No  2.0 [0.8,5.0] 2.4** [1.3,4.3] 1.6 [0.8,3.3]  - - - 
Social support         
Yes  1 1 1  - - - 
No  1.3 [0.6,2.9] 1.8* [1.1,2.9] 0.8 [0.4,1.4]  - - - 
Gender & Social support         
Female & social support  1 1 1  1 1 1 
Female & no social support  1.8 [0.7,4.6] 1.9* [1.0,3.3] 0.5 [0.2,1.3]  2.1 [0.7,6.3] 2.2* [1.1,4.2] 0.6 [0.2,1.5] 
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Male & social support  2.8* [1.3,6.1] 1.2 [0.7,2.2] 1.8* [1.0,3.0]  3.4** [1.4,8.3] 1.4 [0.7,2.7] 1.7 [0.9,3.1] 
Male & no social support  2.4 [0.7,7.8] 1.9 [0.8,4.2] 1.8 [0.8,4.1]  3.0 [0.8,11.3] 1.6 [0.6,4.0] 1.6 [0.6,4.0] 
Time between referral and first 
visit 
 
   
 
   
Less than 1M  1 1 1  - - - 
1-3M  2.6 [1.0,7.1] 0.7 [0.3,1.5] 0.6 [0.2,1.4]  - - - 
More than 3M  3.1** [1.4,7.0] 0.7 [0.4,1.2] 1.1 [0.6,1.9]  - - - 
Newly diagnosed at referral         
No  1 1 1  1 1 1 
Yes  1.2 [0.3,4.1] 5.1*** [2.9,9.0] 6.0*** [3.3,10.8]  0.9 [0.2,3.6] 4.2*** [2.2,8.2] 5.3*** [2.7,10.1] 
CD4 at first visit         
CD4≤350  1 1 1  1 1 1 
CD4 between ]350-500]  9.5*** [3.4,26.6] 0.9 [0.5,1.7] 0.7 [0.4,1.4]  7.7*** [2.6,23.1] 0.7 [0.4,1.4] 0.7 [0.3,1.4] 
CD4>500   7.4*** [2.6,20.7] 1.3 [0.8,2.1] 0.9 [0.5,1.5]  5.1** [1.7,15.4] 0.8 [0.4,1.4] 0.8 [0.4,1.5] 
On ART at M1         
No  1 1 1  1 1 1 
Yes  0.02*** [0.0,0.1] 0.2*** [0.1,0.3] 0.8 [0.5,1.3]  0.03*** [0.0,0.2] 0.2*** [0.1,0.3] 0.8 [0.5,1.3] 
Clusters         
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Clusters with low number of 
patients and HIV prevalence  
 
1 1 1 
 - - - 
Clusters with high number of 
patients and HIV prevalence 
 
4.0** [1.6,9.7] 1.1 [0.7,1.7] 1.3 [0.8,2.0] 
 - - - 
* p < 0.05, ** p < 0.01, *** p < 0.001; OR: odds ratio; aOR: adjusted odds ratio, CI: confidence interval  
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Supplemental Digital Content  
Supplemental Figure 1: Flow-chart of the study population (ANRS 12249 TasP trial) 
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Supplemental Figure 2: Care trajectories in trial clinics over 24 months of clinical follow-
up among patients eligible for ART initiation at the first visit (ANRS 12249 TasP trial, 
n=536) 
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Supplemental Table 1: Sensitivity analysis of factors associated with trajectory groups 
(reference= Group 1 “Remained in care”) when patients who transferred out were 
considered as missing, multivariable analysis (ANRS 12249 TasP trial, n=725) 
 Groups 
Covariates– aOR [95% CI] 
Group 2: exited 
care then returned 
Group 3: exited 
care rapidly 
Group 4: exited 
care later 
Gender & Social support    
Female & social support 1 1 1 
Female & no social support 1.5 [0.5,4.4] 1.9 [0.8,4.1] 0.6 [0.2,1.6] 
Male & social support 3.3** [1.4,7.9] 1.8 [0.9,3.7] 1.8 [0.9,3.4] 
Male & no social support 2.3 [0.5,9.9] 1.9 [0.7,5.0] 1.9 [0.7,4.7] 
Age (years)    
≥40  1 1 1 
30-39 1.0 [0.4,3.0] 1.0 [0.4,2.3] 2.9** [1.3,6.4] 
16-29 3.1* [1.3,7.7] 3.6*** [1.8,7.2] 4.5*** [2.1,9.6] 
Having a regular partner    
Yes 1 1 1 
No 3.3* [1.3,8.1] 1.5 [0.7,3.0] 1.1 [0.5,2.4] 
Newly diagnosed at referral    
No 1 1 1 
Yes 1.1 [0.3,4.4] 5.5*** [2.7,11.1] 6.0*** [3.1,11.7] 
CD4 at first visit    
CD4≤350 1 1 1 
CD4 between ]350-500] 12.1*** [3.3,45.0] 0.5 [0.2,1.2] 0.5 [0.2,1.1] 
CD4>500  9.8*** [2.7,36.1] 0.8 [0.4,1.6] 0.9 [0.5,1.6] 
On ART at M1    
No 1 1 1 
Yes 0.05*** [0.0,0.2] 0.1*** [0.1,0.2] 0.7 [0.4,1.2] 
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* p < 0.05, ** p < 0.01, *** p < 0.001; aOR: adjusted odds ratio 
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Supplemental Table 2: Sensitivity analysis of factors associated with trajectory groups 
(reference= Group 1: remained in care) when patients who transferred out were considered 
as retained in care, multivariable analysis (ANRS 12249 TasP trial, n=735) 
 Groups 
Covariates– aOR [95% CI] 
Group 2: exited 
care then returned 
Group 3: exited 
care rapidly 
Group 4: exited 
care later 
Gender & Social support    
Female & social support 1.0 1.0 1.0 
Female & no social support 1.4 [0.5,4.1] 1.7 [0.8,3.8] 0.5 [0.2,1.4] 
Male & social support 3.2** [1.4,7.5] 1.9 [0.9,3.8] 1.8 [0.9,3.4] 
Male & no social support 2.8 [0.8,10.5] 1.8 [0.7,4.9] 1.6 [0.6,4.2] 
Age (years)    
≥40  1.0 1.0 1.0 
30-39 0.9 [0.3,2.4] 1.0 [0.4,2.3] 3.2** [1.4,7.2] 
16-29 2.5* [1.1,5.9] 3.5*** [1.8,7.0] 4.8*** [2.2,10.3] 
Having a regular partner    
Yes 1.0 1.0 1.0 
No 3.1* [1.3,7.3] 1.5 [0.7,3.1] 1.2 [0.6,2.5] 
Newly diagnosed at referral    
No 1.0 1.0 1.0 
Yes 1.1 [0.3,4.3] 5.3*** [2.6,10.6] 6.2*** [3.2,12.1] 
CD4 at first visit    
CD4≤350 1.0 1.0 1.0 
CD4 between ]350-500] 11.3*** [3.1,41.9] 0.5 [0.2,1.1] 0.5 [0.2,1.1] 
CD4>500  11.1*** [3.1,40.2] 0.8 [0.4,1.6] 0.8 [0.4,1.5] 
On ART at M1    
No 1.0 1.0 1.0 
Yes 0.1*** [0.0,0.2] 0.1*** [0.1,0.2] 0.7 [0.4,1.3] 
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* p < 0.05, ** p < 0.01, *** p < 0.001; aOR: adjusted odds ratio 
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